Basic Searches
Searches without any special characters (listed below) will return items that contain the exact value(s) entered in the search field. This means that searching for "ASPIRIN CALCIUM" won't return any items that have "ASPIRIN GLYCINE CALCIUM" because the search term doesn't match exactly.
Boolean Operators
OR - searches with terms separated by " OR " will return items that contain any of the terms in the search.
Example: "ASPIRIN" OR "CALCIUM" will return items that have strings like "ASPIRIN GLYCINE" and "GLYCINE CALCIUM" because they contain at least one of the terms in the search.

AND - searches with terms separated by " AND " will return items that contain all the terms in the search.
Example: "ASPIRIN" AND "CALCIUM" won't return items that have strings "ASPIRIN GLYCINE" and "GLYCINE CALCIUM" because neither contain both terms, but it will return "ASPIRIN GLYCINE CALCIUM" because it contains both search terms.
version 2.7.1
Substance Class Protein
Protein Type ENZYME
Protein Sub Type CYTOCHROME P450
Sequence Origin HUMAN
Sequence Type COMPLETE
Record UNII
081I12ZA58
Record Status Validated
Record Version
Show Definitional References Hide Definitional References
Download
Name Type Language Details Access References
CYTOCHROME P450 2C19
Common Name
English  
HUMAN CYTOCHROME P450 2C19
Common Name
English  
CYTOCHROME P 450 2C19
Common Name
English  
CYP2C19
Common Name
English  
Code System Code Type Description Access References
CAS
391962-06-4
Created by admin on Wed Aug 04 21:57:43 EDT 2021 , Edited by admin on Wed Aug 04 21:57:43 EDT 2021
ALTERNATIVE
CAS
330589-90-7
Created by admin on Wed Aug 04 21:57:43 EDT 2021 , Edited by admin on Wed Aug 04 21:57:43 EDT 2021
PRIMARY
FDA UNII
081I12ZA58
Created by admin on Wed Aug 04 21:57:43 EDT 2021 , Edited by admin on Wed Aug 04 21:57:43 EDT 2021
PRIMARY
UNIPROT
P33261
Created by admin on Wed Aug 04 21:57:43 EDT 2021 , Edited by admin on Wed Aug 04 21:57:43 EDT 2021
PRIMARY
Related Record Type Details Access References
SUBSTRATE -> METABOLIC ENZYME
none
Mediator Substance Details
none
Created by admin on Wed Aug 04 21:58:00 EDT 2021 , Edited by admin on Wed Aug 04 21:58:00 EDT 2021
SUBSTRATE -> METABOLIC ENZYME
Mediator Substance Details
none
MAJOR
Created by admin on Wed Aug 04 21:58:04 EDT 2021 , Edited by admin on Wed Aug 04 21:58:04 EDT 2021
INHIBITOR -> METABOLIC ENZYME
none
Mediator Substance Details
none
Ki
Created by admin on Wed Aug 04 21:57:48 EDT 2021 , Edited by admin on Wed Aug 04 21:57:48 EDT 2021
SUBSTRATE -> METABOLIC ENZYME
none
Mediator Substance Details
none
Created by admin on Wed Aug 04 21:58:03 EDT 2021 , Edited by admin on Wed Aug 04 21:58:03 EDT 2021
SUBSTRATE -> METABOLIC ENZYME
none
Mediator Substance Details
none
Created by admin on Wed Aug 04 21:57:43 EDT 2021 , Edited by admin on Wed Aug 04 21:57:43 EDT 2021
SUBSTRATE -> METABOLIC ENZYME
none
Mediator Substance Details
none
Created by admin on Wed Aug 04 21:57:57 EDT 2021 , Edited by admin on Wed Aug 04 21:57:57 EDT 2021
INHIBITOR -> METABOLIC ENZYME
none
Mediator Substance Details
none
Created by admin on Wed Aug 04 21:58:05 EDT 2021 , Edited by admin on Wed Aug 04 21:58:05 EDT 2021
SUBSTRATE -> METABOLIC ENZYME
none
Mediator Substance Details
none
Created by admin on Wed Aug 04 21:57:59 EDT 2021 , Edited by admin on Wed Aug 04 21:57:59 EDT 2021
TISSUE EXPRESSION -> PARENT
none
Mediator Substance Details
none
Created by admin on Wed Aug 04 21:57:56 EDT 2021 , Edited by admin on Wed Aug 04 21:57:56 EDT 2021
SUBSTRATE -> METABOLIC ENZYME
none
Mediator Substance Details
none
Created by admin on Wed Aug 04 21:58:05 EDT 2021 , Edited by admin on Wed Aug 04 21:58:05 EDT 2021
INHIBITOR -> METABOLIC ENZYME
none
none
Mediator Substance Details
none
Created by admin on Wed Aug 04 21:57:58 EDT 2021 , Edited by admin on Wed Aug 04 21:57:58 EDT 2021
SUBSTRATE -> METABOLIC ENZYME
Mediator Substance Details
none
MINOR
Created by admin on Wed Aug 04 21:57:57 EDT 2021 , Edited by admin on Wed Aug 04 21:57:57 EDT 2021
INHIBITOR -> METABOLIC ENZYME
none
none
Mediator Substance Details
none
Created by admin on Wed Aug 04 21:57:43 EDT 2021 , Edited by admin on Wed Aug 04 21:57:43 EDT 2021
INHIBITOR -> METABOLIC ENZYME
Mediator Substance Details
none
Ki
Created by admin on Wed Aug 04 21:57:48 EDT 2021 , Edited by admin on Wed Aug 04 21:57:48 EDT 2021
SUBSTRATE -> METABOLIC ENZYME
none
Mediator Substance Details
none
Created by admin on Wed Aug 04 21:58:01 EDT 2021 , Edited by admin on Wed Aug 04 21:58:01 EDT 2021
SUBSTRATE -> METABOLIC ENZYME
none
Mediator Substance Details
none
Created by admin on Wed Aug 04 21:57:59 EDT 2021 , Edited by admin on Wed Aug 04 21:57:59 EDT 2021
SUBSTRATE -> METABOLIC ENZYME
none
Mediator Substance Details
none
Created by admin on Wed Aug 04 21:57:55 EDT 2021 , Edited by admin on Wed Aug 04 21:57:55 EDT 2021
SUBSTRATE -> METABOLIC ENZYME
Mediator Substance Details
none
MINOR
Created by admin on Wed Aug 04 21:58:04 EDT 2021 , Edited by admin on Wed Aug 04 21:58:04 EDT 2021
SUBSTRATE -> METABOLIC ENZYME
none
Mediator Substance Details
none
Created by admin on Wed Aug 04 21:58:01 EDT 2021 , Edited by admin on Wed Aug 04 21:58:01 EDT 2021
INHIBITOR -> METABOLIC ENZYME
Mediator Substance Details
none
MODERATE
Created by admin on Wed Aug 04 21:58:05 EDT 2021 , Edited by admin on Wed Aug 04 21:58:05 EDT 2021
NON-INHIBITOR -> METABOLIC ENZYME
none
none
Mediator Substance Details
none
Created by admin on Wed Aug 04 21:57:55 EDT 2021 , Edited by admin on Wed Aug 04 21:57:55 EDT 2021
SUBSTRATE -> METABOLIC ENZYME
none
Mediator Substance Details
none
Created by admin on Wed Aug 04 21:58:04 EDT 2021 , Edited by admin on Wed Aug 04 21:58:04 EDT 2021
SUBSTRATE -> METABOLIC ENZYME
none
Mediator Substance Details
none
Created by admin on Wed Aug 04 21:58:01 EDT 2021 , Edited by admin on Wed Aug 04 21:58:01 EDT 2021
SUBSTRATE -> METABOLIC ENZYME
Mediator Substance Details
none
MINOR
Created by admin on Wed Aug 04 21:58:01 EDT 2021 , Edited by admin on Wed Aug 04 21:58:01 EDT 2021
INHIBITOR -> METABOLIC ENZYME
none
Mediator Substance Details
none
Created by admin on Wed Aug 04 21:58:00 EDT 2021 , Edited by admin on Wed Aug 04 21:58:00 EDT 2021
NON-SUBSTRATE -> METABOLIC ENZYME
none
none
Mediator Substance Details
none
Created by admin on Wed Aug 04 21:57:43 EDT 2021 , Edited by admin on Wed Aug 04 21:57:43 EDT 2021
INDUCER -> METABOLIC ENZYME
Mediator Substance Details
none
WEAK
Zanubrutinib is a weak inducer of CYP3A4 and CYP2C19 in vivo.
Created by admin on Wed Aug 04 21:58:02 EDT 2021 , Edited by admin on Wed Aug 04 21:58:02 EDT 2021
INHIBITOR -> METABOLIC ENZYME
none
Mediator Substance Details
none
Created by admin on Wed Aug 04 21:58:01 EDT 2021 , Edited by admin on Wed Aug 04 21:58:01 EDT 2021
SUBSTRATE -> METABOLIC ENZYME
Mediator Substance Details
none
MINOR
Created by admin on Wed Aug 04 21:58:05 EDT 2021 , Edited by admin on Wed Aug 04 21:58:05 EDT 2021
SUBSTRATE -> METABOLIC ENZYME
none
Mediator Substance Details
none
Created by admin on Wed Aug 04 21:58:02 EDT 2021 , Edited by admin on Wed Aug 04 21:58:02 EDT 2021
SUBSTRATE -> METABOLIC ENZYME
none
Mediator Substance Details
none
Created by admin on Wed Aug 04 21:58:03 EDT 2021 , Edited by admin on Wed Aug 04 21:58:03 EDT 2021
SUBSTRATE -> METABOLIC ENZYME
none
Mediator Substance Details
none
Created by admin on Wed Aug 04 21:57:57 EDT 2021 , Edited by admin on Wed Aug 04 21:57:57 EDT 2021
INDUCER -> TARGET
none
Mediator Substance Details
none
Created by admin on Wed Aug 04 21:58:05 EDT 2021 , Edited by admin on Wed Aug 04 21:58:05 EDT 2021
SUBSTRATE -> METABOLIC ENZYME
Mediator Substance Details
none
MINOR
Created by admin on Wed Aug 04 21:58:03 EDT 2021 , Edited by admin on Wed Aug 04 21:58:03 EDT 2021
INHIBITOR -> METABOLIC ENZYME
none
Mediator Substance Details
none
Created by admin on Wed Aug 04 21:58:00 EDT 2021 , Edited by admin on Wed Aug 04 21:58:00 EDT 2021
INHIBITOR -> METABOLIC ENZYME
Mediator Substance Details
none
WEAK
Created by admin on Wed Aug 04 21:57:56 EDT 2021 , Edited by admin on Wed Aug 04 21:57:56 EDT 2021
SUBSTRATE -> METABOLIC ENZYME
Mediator Substance Details
none
IN VITRO
Created by admin on Wed Aug 04 21:57:56 EDT 2021 , Edited by admin on Wed Aug 04 21:57:56 EDT 2021
SUBSTRATE -> METABOLIC ENZYME
none
Mediator Substance Details
none
Created by admin on Wed Aug 04 21:58:00 EDT 2021 , Edited by admin on Wed Aug 04 21:58:00 EDT 2021
SUBSTRATE -> METABOLIC ENZYME
none
Mediator Substance Details
none
Created by admin on Wed Aug 04 21:58:05 EDT 2021 , Edited by admin on Wed Aug 04 21:58:05 EDT 2021
SUBSTRATE -> METABOLIC ENZYME
none
Mediator Substance Details
none
Created by admin on Wed Aug 04 21:57:58 EDT 2021 , Edited by admin on Wed Aug 04 21:57:58 EDT 2021
INHIBITOR -> METABOLIC ENZYME
Mediator Substance Details
none
REVERSIBLE INHIBITION
IC50
Created by admin on Wed Aug 04 21:58:03 EDT 2021 , Edited by admin on Wed Aug 04 21:58:03 EDT 2021
SUBSTRATE -> METABOLIC ENZYME
none
none
Mediator Substance Details
none
Created by admin on Wed Aug 04 21:57:56 EDT 2021 , Edited by admin on Wed Aug 04 21:57:56 EDT 2021
SUBSTRATE -> METABOLIC ENZYME
none
Mediator Substance Details
none
Created by admin on Wed Aug 04 21:58:03 EDT 2021 , Edited by admin on Wed Aug 04 21:58:03 EDT 2021
SUBSTRATE -> METABOLIC ENZYME
none
Mediator Substance Details
none
Created by admin on Wed Aug 04 21:57:57 EDT 2021 , Edited by admin on Wed Aug 04 21:57:57 EDT 2021
SUBSTRATE -> METABOLIC ENZYME
none
Mediator Substance Details
none
CYP2C19 preferentially metabolized (R)-methadone,
Created by admin on Wed Aug 04 21:57:43 EDT 2021 , Edited by admin on Wed Aug 04 21:57:43 EDT 2021
SUBSTRATE -> METABOLIC ENZYME
Mediator Substance Details
none
MAJOR
Created by admin on Wed Aug 04 21:58:05 EDT 2021 , Edited by admin on Wed Aug 04 21:58:05 EDT 2021
SUBSTRATE -> METABOLIC ENZYME
none
Mediator Substance Details
none
Created by admin on Wed Aug 04 21:58:04 EDT 2021 , Edited by admin on Wed Aug 04 21:58:04 EDT 2021
INHIBITOR -> METABOLIC ENZYME
none
none
Mediator Substance Details
none
Created by admin on Wed Aug 04 21:58:04 EDT 2021 , Edited by admin on Wed Aug 04 21:58:04 EDT 2021
NON-SUBSTRATE -> METABOLIC ENZYME
none
Mediator Substance Details
none
Created by admin on Wed Aug 04 21:58:01 EDT 2021 , Edited by admin on Wed Aug 04 21:58:01 EDT 2021
SUBSTRATE -> METABOLIC ENZYME
none
Mediator Substance Details
none
Created by admin on Wed Aug 04 21:58:00 EDT 2021 , Edited by admin on Wed Aug 04 21:58:00 EDT 2021
INHIBITOR -> METABOLIC ENZYME
Mediator Substance Details
none
REVERSIBLE
Created by admin on Wed Aug 04 21:58:03 EDT 2021 , Edited by admin on Wed Aug 04 21:58:03 EDT 2021
SUBSTRATE -> METABOLIC ENZYME
Mediator Substance Details
none
At higher than clinical concentrations, ixazomib was metabolized by multiple CYP isoforms with estimated relative contributions of 3A4 (42%), 1A2 (26%), 2B6 (16%), 2C8 (6%), 2D6 (5%), 2C19 (5%) and 2C9 (< 1%).
Created by admin on Wed Aug 04 21:58:01 EDT 2021 , Edited by admin on Wed Aug 04 21:58:01 EDT 2021
INHIBITOR -> METABOLIC ENZYME
Mediator Substance Details
none
IC50
Created by admin on Wed Aug 04 21:58:02 EDT 2021 , Edited by admin on Wed Aug 04 21:58:02 EDT 2021
SUBSTRATE -> METABOLIC ENZYME
none
Mediator Substance Details
none
Created by admin on Wed Aug 04 21:58:00 EDT 2021 , Edited by admin on Wed Aug 04 21:58:00 EDT 2021
SUBSTRATE -> METABOLIC ENZYME
none
Mediator Substance Details
none
Created by admin on Wed Aug 04 21:57:57 EDT 2021 , Edited by admin on Wed Aug 04 21:57:57 EDT 2021
SUBSTRATE -> METABOLIC ENZYME
none
Mediator Substance Details
none
Created by admin on Wed Aug 04 21:57:57 EDT 2021 , Edited by admin on Wed Aug 04 21:57:57 EDT 2021
SUBSTRATE -> METABOLIC ENZYME
none
Mediator Substance Details
none
Created by admin on Wed Aug 04 21:58:02 EDT 2021 , Edited by admin on Wed Aug 04 21:58:02 EDT 2021
SUBSTRATE -> METABOLIC ENZYME
none
Mediator Substance Details
none
Created by admin on Wed Aug 04 21:57:59 EDT 2021 , Edited by admin on Wed Aug 04 21:57:59 EDT 2021
SUBSTRATE -> METABOLIC ENZYME
Mediator Substance Details
none
MINOR
Created by admin on Wed Aug 04 21:58:04 EDT 2021 , Edited by admin on Wed Aug 04 21:58:04 EDT 2021
SUBSTRATE -> METABOLIC ENZYME
Mediator Substance Details
none
CYP1A2, CYP2C9, and CYP2C19 are involved in the metabolism of diphenhydramine as low-affinity P450 isozymes.
Created by admin on Wed Aug 04 21:57:57 EDT 2021 , Edited by admin on Wed Aug 04 21:57:57 EDT 2021
INDUCER -> METABOLIC ENZYME
Mediator Substance Details
none
POTENT
Created by admin on Wed Aug 04 21:57:48 EDT 2021 , Edited by admin on Wed Aug 04 21:57:48 EDT 2021
SUBSTRATE -> METABOLIC ENZYME
none
Mediator Substance Details
none
Created by admin on Wed Aug 04 21:57:53 EDT 2021 , Edited by admin on Wed Aug 04 21:57:53 EDT 2021
INDUCER -> METABOLIC ENZYME
Mediator Substance Details
none
POTENT
Created by admin on Wed Aug 04 21:57:50 EDT 2021 , Edited by admin on Wed Aug 04 21:57:50 EDT 2021
INHIBITOR -> METABOLIC ENZYME
Mediator Substance Details
none
MINOR
Created by admin on Wed Aug 04 21:58:05 EDT 2021 , Edited by admin on Wed Aug 04 21:58:05 EDT 2021
SUBSTRATE -> METABOLIC ENZYME
none
Mediator Substance Details
none
Created by admin on Wed Aug 04 21:58:03 EDT 2021 , Edited by admin on Wed Aug 04 21:58:03 EDT 2021
INHIBITOR -> METABOLIC ENZYME
Mediator Substance Details
none
WEAK
IC50
Created by admin on Wed Aug 04 21:58:04 EDT 2021 , Edited by admin on Wed Aug 04 21:58:04 EDT 2021
INHIBITOR -> METABOLIC ENZYME
Mediator Substance Details
none
IC50
Created by admin on Wed Aug 04 21:58:03 EDT 2021 , Edited by admin on Wed Aug 04 21:58:03 EDT 2021
INHIBITOR -> METABOLIC ENZYME
Mediator Substance Details
none
In vitro studies have shown that vilazodone is a moderate inhibitor of CYP2C19 and CYP2D6
Created by admin on Wed Aug 04 21:58:04 EDT 2021 , Edited by admin on Wed Aug 04 21:58:04 EDT 2021
SUBSTRATE -> METABOLIC ENZYME
none
Mediator Substance Details
none
Created by admin on Wed Aug 04 21:57:58 EDT 2021 , Edited by admin on Wed Aug 04 21:57:58 EDT 2021
INHIBITOR -> METABOLIC ENZYME
Mediator Substance Details
none
TIME-DEPENDENT INHIBITION
Pretomanid is a weak time-dependent inhibitor of CYP2C8 and CYP2C19.
Created by admin on Wed Aug 04 21:58:02 EDT 2021 , Edited by admin on Wed Aug 04 21:58:02 EDT 2021
NON-INHIBITOR -> METABOLIC ENZYME
none
Mediator Substance Details
none
Created by admin on Wed Aug 04 21:58:04 EDT 2021 , Edited by admin on Wed Aug 04 21:58:04 EDT 2021
SUBSTRATE -> METABOLIC ENZYME
none
Mediator Substance Details
none
Created by admin on Wed Aug 04 21:58:03 EDT 2021 , Edited by admin on Wed Aug 04 21:58:03 EDT 2021
SUBSTRATE -> METABOLIC ENZYME
none
Mediator Substance Details
none
Created by admin on Wed Aug 04 21:58:00 EDT 2021 , Edited by admin on Wed Aug 04 21:58:00 EDT 2021
SUBSTRATE -> METABOLIC ENZYME
none
Mediator Substance Details
none
Created by admin on Wed Aug 04 21:57:56 EDT 2021 , Edited by admin on Wed Aug 04 21:57:56 EDT 2021
SUBSTRATE -> METABOLIC ENZYME
none
Mediator Substance Details
none
Created by admin on Wed Aug 04 21:58:02 EDT 2021 , Edited by admin on Wed Aug 04 21:58:02 EDT 2021
SUBSTRATE -> METABOLIC ENZYME
Mediator Substance Details
none
MINOR
Created by admin on Wed Aug 04 21:58:04 EDT 2021 , Edited by admin on Wed Aug 04 21:58:04 EDT 2021
INDUCER -> METABOLIC ENZYME
Mediator Substance Details
none
POTENT
Created by admin on Wed Aug 04 21:57:50 EDT 2021 , Edited by admin on Wed Aug 04 21:57:50 EDT 2021
INHIBITOR -> METABOLIC ENZYME
Mediator Substance Details
none
IC50
Created by admin on Wed Aug 04 21:58:05 EDT 2021 , Edited by admin on Wed Aug 04 21:58:05 EDT 2021
INDUCER -> METABOLIC ENZYME
Mediator Substance Details
none
POTENT
Created by admin on Wed Aug 04 21:57:49 EDT 2021 , Edited by admin on Wed Aug 04 21:57:49 EDT 2021
INHIBITOR -> METABOLIC ENZYME
Mediator Substance Details
none
Rifamycin is an inhibitor of CYP1A2, 2B6, 2C8, 2C9, 2C19, 2D6 and 3A4/5 in vitro, however, based on systemic concentrations of rifamycin observed after administration of the recommended dose clinically relevant inhibition of these enzymes in vivo is unlikely.
Created by admin on Wed Aug 04 21:58:05 EDT 2021 , Edited by admin on Wed Aug 04 21:58:05 EDT 2021
SUBSTRATE -> METABOLIC ENZYME
none
none
Mediator Substance Details
none
Created by admin on Wed Aug 04 21:58:04 EDT 2021 , Edited by admin on Wed Aug 04 21:58:04 EDT 2021
SUBSTRATE -> METABOLIC ENZYME
Mediator Substance Details
none
MINOR
Created by admin on Wed Aug 04 21:57:57 EDT 2021 , Edited by admin on Wed Aug 04 21:57:57 EDT 2021
INHIBITOR -> METABOLIC ENZYME
Mediator Substance Details
none
IN VITRO
Created by admin on Wed Aug 04 21:57:56 EDT 2021 , Edited by admin on Wed Aug 04 21:57:56 EDT 2021
INHIBITOR -> METABOLIC ENZYME
Mediator Substance Details
none
TIME-DEPENDENT INHIBITION
Ki
Created by admin on Wed Aug 04 21:58:03 EDT 2021 , Edited by admin on Wed Aug 04 21:58:03 EDT 2021
SUBSTRATE -> METABOLIC ENZYME
Mediator Substance Details
none
MINOR
Created by admin on Wed Aug 04 21:58:03 EDT 2021 , Edited by admin on Wed Aug 04 21:58:03 EDT 2021
INHIBITOR -> METABOLIC ENZYME
none
none
Mediator Substance Details
none
Created by admin on Wed Aug 04 21:57:43 EDT 2021 , Edited by admin on Wed Aug 04 21:57:43 EDT 2021
SUBSTRATE -> METABOLIC ENZYME
none
Mediator Substance Details
none
Created by admin on Wed Aug 04 21:57:46 EDT 2021 , Edited by admin on Wed Aug 04 21:57:46 EDT 2021
SUBSTRATE -> METABOLIC ENZYME
Mediator Substance Details
none
IN VITRO
Created by admin on Wed Aug 04 21:57:56 EDT 2021 , Edited by admin on Wed Aug 04 21:57:56 EDT 2021
SUBSTRATE -> METABOLIC ENZYME
none
none
Mediator Substance Details
none
Created by admin on Wed Aug 04 21:58:05 EDT 2021 , Edited by admin on Wed Aug 04 21:58:05 EDT 2021
SUBSTRATE -> METABOLIC ENZYME
Mediator Substance Details
none
MINOR
Created by admin on Wed Aug 04 21:58:04 EDT 2021 , Edited by admin on Wed Aug 04 21:58:04 EDT 2021
SUBSTRATE -> METABOLIC ENZYME
none
Mediator Substance Details
none
Created by admin on Wed Aug 04 21:58:05 EDT 2021 , Edited by admin on Wed Aug 04 21:58:05 EDT 2021
INHIBITOR -> METABOLIC ENZYME
Mediator Substance Details
none
IC50
Created by admin on Wed Aug 04 21:58:02 EDT 2021 , Edited by admin on Wed Aug 04 21:58:02 EDT 2021
SUBSTRATE -> METABOLIC ENZYME
none
Mediator Substance Details
none
Created by admin on Wed Aug 04 21:57:59 EDT 2021 , Edited by admin on Wed Aug 04 21:57:59 EDT 2021
SUBSTRATE -> METABOLIC ENZYME
none
Mediator Substance Details
none
Created by admin on Wed Aug 04 21:57:55 EDT 2021 , Edited by admin on Wed Aug 04 21:57:55 EDT 2021
INHIBITOR -> TARGET
Mediator Substance Details
none
Ki
Created by admin on Wed Aug 04 21:58:05 EDT 2021 , Edited by admin on Wed Aug 04 21:58:05 EDT 2021
INDUCER -> METABOLIC ENZYME
none
none
Mediator Substance Details
none
Created by admin on Wed Aug 04 21:58:05 EDT 2021 , Edited by admin on Wed Aug 04 21:58:05 EDT 2021
INHIBITOR -> METABOLIC ENZYME
none
Mediator Substance Details
none
Created by admin on Wed Aug 04 21:57:44 EDT 2021 , Edited by admin on Wed Aug 04 21:57:44 EDT 2021
SUBSTRATE -> METABOLIC ENZYME
none
Mediator Substance Details
none
Created by admin on Wed Aug 04 21:57:59 EDT 2021 , Edited by admin on Wed Aug 04 21:57:59 EDT 2021
SUBSTRATE -> METABOLIC ENZYME
none
Mediator Substance Details
none
Created by admin on Wed Aug 04 21:57:54 EDT 2021 , Edited by admin on Wed Aug 04 21:57:54 EDT 2021
SUBSTRATE -> METABOLIC ENZYME
none
Mediator Substance Details
none
Created by admin on Wed Aug 04 21:58:04 EDT 2021 , Edited by admin on Wed Aug 04 21:58:04 EDT 2021
SUBSTRATE -> METABOLIC ENZYME
none
Mediator Substance Details
none
Created by admin on Wed Aug 04 21:58:00 EDT 2021 , Edited by admin on Wed Aug 04 21:58:00 EDT 2021
SUBSTRATE -> METABOLIC ENZYME
Mediator Substance Details
none
MINOR
Created by admin on Wed Aug 04 21:57:57 EDT 2021 , Edited by admin on Wed Aug 04 21:57:57 EDT 2021
SUBSTRATE -> METABOLIC ENZYME
none
Mediator Substance Details
none
Created by admin on Wed Aug 04 21:57:57 EDT 2021 , Edited by admin on Wed Aug 04 21:57:57 EDT 2021
SUBSTRATE -> METABOLIC ENZYME
Mediator Substance Details
none
MAJOR
Ospemifene is primarily metabolized by CYP3A4, 2C9, and 2C19 responsible for approximately 40 to 50%, ~25%, and ~25%, respectively, of its clearance.
Created by admin on Wed Aug 04 21:58:01 EDT 2021 , Edited by admin on Wed Aug 04 21:58:01 EDT 2021
SUBSTRATE -> METABOLIC ENZYME
Mediator Substance Details
none
MINOR
Created by admin on Wed Aug 04 21:58:05 EDT 2021 , Edited by admin on Wed Aug 04 21:58:05 EDT 2021
NON-SUBSTRATE -> METABOLIC ENZYME
none
Mediator Substance Details
none
Created by admin on Wed Aug 04 21:58:04 EDT 2021 , Edited by admin on Wed Aug 04 21:58:04 EDT 2021
SUBSTRATE -> METABOLIC ENZYME
Mediator Substance Details
none
MINOR
Created by admin on Wed Aug 04 21:57:57 EDT 2021 , Edited by admin on Wed Aug 04 21:57:57 EDT 2021
INHIBITOR -> METABOLIC ENZYME
Mediator Substance Details
none
IC50
Created by admin on Wed Aug 04 21:58:02 EDT 2021 , Edited by admin on Wed Aug 04 21:58:02 EDT 2021
SUBSTRATE -> METABOLIC ENZYME
Mediator Substance Details
none
MINOR
Created by admin on Wed Aug 04 21:57:57 EDT 2021 , Edited by admin on Wed Aug 04 21:57:57 EDT 2021
SUBSTRATE -> METABOLIC ENZYME
none
none
Mediator Substance Details
none
Created by admin on Wed Aug 04 21:58:05 EDT 2021 , Edited by admin on Wed Aug 04 21:58:05 EDT 2021
SUBSTRATE -> METABOLIC ENZYME
none
Mediator Substance Details
none
Created by admin on Wed Aug 04 21:57:59 EDT 2021 , Edited by admin on Wed Aug 04 21:57:59 EDT 2021
INDUCER -> METABOLIC ENZYME
none
Mediator Substance Details
none
Created by admin on Wed Aug 04 21:57:46 EDT 2021 , Edited by admin on Wed Aug 04 21:57:46 EDT 2021
INHIBITOR -> METABOLIC ENZYME
none
Mediator Substance Details
none
Created by admin on Wed Aug 04 21:58:00 EDT 2021 , Edited by admin on Wed Aug 04 21:58:00 EDT 2021
INHIBITOR -> METABOLIC ENZYME
none
none
Mediator Substance Details
none
Created by admin on Wed Aug 04 21:57:43 EDT 2021 , Edited by admin on Wed Aug 04 21:57:43 EDT 2021
SUBSTRATE -> METABOLIC ENZYME
none
none
Mediator Substance Details
none
Created by admin on Wed Aug 04 21:57:43 EDT 2021 , Edited by admin on Wed Aug 04 21:57:43 EDT 2021
SUBSTRATE -> METABOLIC ENZYME
Mediator Substance Details
none
MINOR
Created by admin on Wed Aug 04 21:57:58 EDT 2021 , Edited by admin on Wed Aug 04 21:57:58 EDT 2021
SUBSTRATE -> METABOLIC ENZYME
none
Mediator Substance Details
none
Created by admin on Wed Aug 04 21:58:04 EDT 2021 , Edited by admin on Wed Aug 04 21:58:04 EDT 2021
SUBSTRATE -> METABOLIC ENZYME
none
Mediator Substance Details
none
Created by admin on Wed Aug 04 21:58:00 EDT 2021 , Edited by admin on Wed Aug 04 21:58:00 EDT 2021
SUBSTRATE -> METABOLIC ENZYME
none
Mediator Substance Details
none
Created by admin on Wed Aug 04 21:57:58 EDT 2021 , Edited by admin on Wed Aug 04 21:57:58 EDT 2021
SUBSTRATE -> METABOLIC ENZYME
none
Mediator Substance Details
none
Created by admin on Wed Aug 04 21:57:52 EDT 2021 , Edited by admin on Wed Aug 04 21:57:52 EDT 2021
INHIBITOR -> METABOLIC ENZYME
none
Mediator Substance Details
none
Created by admin on Wed Aug 04 21:58:00 EDT 2021 , Edited by admin on Wed Aug 04 21:58:00 EDT 2021
INHIBITOR -> METABOLIC ENZYME
Mediator Substance Details
none
IC50
Created by admin on Wed Aug 04 21:58:03 EDT 2021 , Edited by admin on Wed Aug 04 21:58:03 EDT 2021
SUBSTRATE -> METABOLIC ENZYME
Mediator Substance Details
none
MINOR
Created by admin on Wed Aug 04 21:58:02 EDT 2021 , Edited by admin on Wed Aug 04 21:58:02 EDT 2021
SUBSTRATE -> METABOLIC ENZYME
none
Mediator Substance Details
none
Created by admin on Wed Aug 04 21:58:05 EDT 2021 , Edited by admin on Wed Aug 04 21:58:05 EDT 2021
SUBSTRATE -> METABOLIC ENZYME
none
Mediator Substance Details
none
Created by admin on Wed Aug 04 21:58:05 EDT 2021 , Edited by admin on Wed Aug 04 21:58:05 EDT 2021
SUBSTRATE -> METABOLIC ENZYME
Mediator Substance Details
none
Created by admin on Wed Aug 04 21:57:57 EDT 2021 , Edited by admin on Wed Aug 04 21:57:57 EDT 2021
INHIBITOR -> METABOLIC ENZYME
none
Mediator Substance Details
none
Created by admin on Wed Aug 04 21:58:00 EDT 2021 , Edited by admin on Wed Aug 04 21:58:00 EDT 2021
NON-INHIBITOR -> METABOLIC ENZYME
none
none
Mediator Substance Details
none
Created by admin on Wed Aug 04 21:57:43 EDT 2021 , Edited by admin on Wed Aug 04 21:57:43 EDT 2021
INHIBITOR -> METABOLIC ENZYME
Mediator Substance Details
none
SELECTIVE
Created by admin on Wed Aug 04 21:58:00 EDT 2021 , Edited by admin on Wed Aug 04 21:58:00 EDT 2021
INHIBITOR -> METABOLIC ENZYME
none
Mediator Substance Details
none
Created by admin on Wed Aug 04 21:57:57 EDT 2021 , Edited by admin on Wed Aug 04 21:57:57 EDT 2021
NON-INHIBITOR -> METABOLIC ENZYME
none
none
Mediator Substance Details
none
Created by admin on Wed Aug 04 21:57:43 EDT 2021 , Edited by admin on Wed Aug 04 21:57:43 EDT 2021
INHIBITOR -> METABOLIC ENZYME
Mediator Substance Details
none
MAJOR
MIXED INHIBITION
Ki
Created by admin on Wed Aug 04 21:57:44 EDT 2021 , Edited by admin on Wed Aug 04 21:57:44 EDT 2021
INHIBITOR -> METABOLIC ENZYME
none
Mediator Substance Details
none
Created by admin on Wed Aug 04 21:57:57 EDT 2021 , Edited by admin on Wed Aug 04 21:57:57 EDT 2021
SUBSTRATE -> METABOLIC ENZYME
Mediator Substance Details
none
MAJOR
Created by admin on Wed Aug 04 21:58:00 EDT 2021 , Edited by admin on Wed Aug 04 21:58:00 EDT 2021
INHIBITOR -> METABOLIC ENZYME
none
none
Mediator Substance Details
none
Created by admin on Wed Aug 04 21:57:43 EDT 2021 , Edited by admin on Wed Aug 04 21:57:43 EDT 2021
SUBSTRATE -> METABOLIC ENZYME
Mediator Substance Details
none
MINOR
Created by admin on Wed Aug 04 21:57:57 EDT 2021 , Edited by admin on Wed Aug 04 21:57:57 EDT 2021
SUBSTRATE -> METABOLIC ENZYME
none
Mediator Substance Details
none
Created by admin on Wed Aug 04 21:57:59 EDT 2021 , Edited by admin on Wed Aug 04 21:57:59 EDT 2021
SUBSTRATE -> METABOLIC ENZYME
none
Mediator Substance Details
none
Created by admin on Wed Aug 04 21:57:47 EDT 2021 , Edited by admin on Wed Aug 04 21:57:47 EDT 2021
INHIBITOR -> METABOLIC ENZYME
Mediator Substance Details
none
IC50
Created by admin on Wed Aug 04 21:58:01 EDT 2021 , Edited by admin on Wed Aug 04 21:58:01 EDT 2021
SUBSTRATE -> METABOLIC ENZYME
none
Mediator Substance Details
none
Created by admin on Wed Aug 04 21:58:03 EDT 2021 , Edited by admin on Wed Aug 04 21:58:03 EDT 2021
INHIBITOR -> METABOLIC ENZYME
Mediator Substance Details
none
IC50
Created by admin on Wed Aug 04 21:58:04 EDT 2021 , Edited by admin on Wed Aug 04 21:58:04 EDT 2021
SUBSTRATE -> METABOLIC ENZYME
none
Mediator Substance Details
none
Created by admin on Wed Aug 04 21:57:46 EDT 2021 , Edited by admin on Wed Aug 04 21:57:46 EDT 2021
INHIBITOR -> METABOLIC ENZYME
none
Mediator Substance Details
none
Created by admin on Wed Aug 04 21:58:00 EDT 2021 , Edited by admin on Wed Aug 04 21:58:00 EDT 2021
SUBSTRATE -> METABOLIC ENZYME
none
Mediator Substance Details
none
MINOR
Created by admin on Wed Aug 04 21:57:58 EDT 2021 , Edited by admin on Wed Aug 04 21:57:58 EDT 2021
SUBSTRATE -> METABOLIC ENZYME
none
Mediator Substance Details
none
Created by admin on Wed Aug 04 21:58:01 EDT 2021 , Edited by admin on Wed Aug 04 21:58:01 EDT 2021
SUBSTRATE -> METABOLIC ENZYME
Mediator Substance Details
none
MINOR
Created by admin on Wed Aug 04 21:57:56 EDT 2021 , Edited by admin on Wed Aug 04 21:57:56 EDT 2021
SUBSTRATE -> METABOLIC ENZYME
Mediator Substance Details
none
MINOR
Created by admin on Wed Aug 04 21:58:02 EDT 2021 , Edited by admin on Wed Aug 04 21:58:02 EDT 2021
NON-SUBSTRATE -> METABOLIC ENZYME
none
none
Mediator Substance Details
none
Created by admin on Wed Aug 04 21:57:56 EDT 2021 , Edited by admin on Wed Aug 04 21:57:56 EDT 2021
NON-INHIBITOR -> METABOLIC ENZYME
none
Mediator Substance Details
none
Created by admin on Wed Aug 04 21:58:05 EDT 2021 , Edited by admin on Wed Aug 04 21:58:05 EDT 2021
SUBSTRATE -> METABOLIC ENZYME
Mediator Substance Details
none
MINOR
Created by admin on Wed Aug 04 21:58:01 EDT 2021 , Edited by admin on Wed Aug 04 21:58:01 EDT 2021
SUBSTRATE -> METABOLIC ENZYME
none
Mediator Substance Details
none
Created by admin on Wed Aug 04 21:58:04 EDT 2021 , Edited by admin on Wed Aug 04 21:58:04 EDT 2021
SUBSTRATE -> METABOLIC ENZYME
Mediator Substance Details
none
MINOR
Created by admin on Wed Aug 04 21:58:02 EDT 2021 , Edited by admin on Wed Aug 04 21:58:02 EDT 2021
INHIBITOR -> METABOLIC ENZYME
Mediator Substance Details
none
POTENT
Created by admin on Wed Aug 04 21:57:50 EDT 2021 , Edited by admin on Wed Aug 04 21:57:50 EDT 2021
SUBSTRATE -> METABOLIC ENZYME
none
none
Mediator Substance Details
none
Created by admin on Wed Aug 04 21:58:05 EDT 2021 , Edited by admin on Wed Aug 04 21:58:05 EDT 2021
SUBSTRATE -> METABOLIC ENZYME
Mediator Substance Details
none
Metabolized by CYP3A4 (0 to 70%), CYP2C19 (0?20%), and FMO3 (0?33%) in vitro.
Created by admin on Wed Aug 04 21:58:02 EDT 2021 , Edited by admin on Wed Aug 04 21:58:02 EDT 2021
INHIBITOR -> METABOLIC ENZYME
Mediator Substance Details
none
IC50
Created by admin on Wed Aug 04 21:57:57 EDT 2021 , Edited by admin on Wed Aug 04 21:57:57 EDT 2021
SUBSTRATE -> METABOLIC ENZYME
none
Mediator Substance Details
none
Created by admin on Wed Aug 04 21:57:46 EDT 2021 , Edited by admin on Wed Aug 04 21:57:46 EDT 2021
SUBSTRATE -> METABOLIC ENZYME
none
Mediator Substance Details
none
Created by admin on Wed Aug 04 21:58:03 EDT 2021 , Edited by admin on Wed Aug 04 21:58:03 EDT 2021
SUBSTRATE -> METABOLIC ENZYME
none
Mediator Substance Details
none
Created by admin on Wed Aug 04 21:58:02 EDT 2021 , Edited by admin on Wed Aug 04 21:58:02 EDT 2021
SUBSTRATE -> METABOLIC ENZYME
Mediator Substance Details
none
MINOR
Created by admin on Wed Aug 04 21:58:05 EDT 2021 , Edited by admin on Wed Aug 04 21:58:05 EDT 2021
SUBSTRATE -> METABOLIC ENZYME
Mediator Substance Details
none
MINOR
Created by admin on Wed Aug 04 21:57:58 EDT 2021 , Edited by admin on Wed Aug 04 21:57:58 EDT 2021
SUBSTRATE -> METABOLIC ENZYME
Mediator Substance Details
none
Created by admin on Wed Aug 04 21:58:03 EDT 2021 , Edited by admin on Wed Aug 04 21:58:03 EDT 2021
SUBSTRATE -> METABOLIC ENZYME
Mediator Substance Details
none
In vitro metabolism studies involving recombinant enzymes indicated that CYP3A4, CYP1A1, CYP3A5, CYP2C9, CYP2C19 and CYP2B6 were responsible for the oxidative metabolism of voxelotor.
Created by admin on Wed Aug 04 21:57:57 EDT 2021 , Edited by admin on Wed Aug 04 21:57:57 EDT 2021
SUBSTRATE -> METABOLIC ENZYME
none
Mediator Substance Details
none
Created by admin on Wed Aug 04 21:57:43 EDT 2021 , Edited by admin on Wed Aug 04 21:57:43 EDT 2021
INDUCER -> METABOLIC ENZYME
none
Mediator Substance Details
none
MODERATE
Therefore, co-administration of enzalutamide with CYP3A4, 2C9, and 2C19 substrates with a narrow therapeutic index should be avoided.
Created by admin on Wed Aug 04 21:57:58 EDT 2021 , Edited by admin on Wed Aug 04 21:57:58 EDT 2021
SUBSTRATE -> METABOLIC ENZYME
Mediator Substance Details
none
Created by admin on Wed Aug 04 21:58:02 EDT 2021 , Edited by admin on Wed Aug 04 21:58:02 EDT 2021
INHIBITOR -> TARGET
Mediator Substance Details
none
MINOR
Created by admin on Wed Aug 04 21:58:05 EDT 2021 , Edited by admin on Wed Aug 04 21:58:05 EDT 2021
SUBSTRATE -> METABOLIC ENZYME
none
Mediator Substance Details
none
Created by admin on Wed Aug 04 21:57:47 EDT 2021 , Edited by admin on Wed Aug 04 21:57:47 EDT 2021
SUBSTRATE -> METABOLIC ENZYME
Mediator Substance Details
none
MAJOR
Created by admin on Wed Aug 04 21:58:01 EDT 2021 , Edited by admin on Wed Aug 04 21:58:01 EDT 2021
SUBSTRATE -> METABOLIC ENZYME
none
none
Mediator Substance Details
none
Created by admin on Wed Aug 04 21:57:43 EDT 2021 , Edited by admin on Wed Aug 04 21:57:43 EDT 2021
INHIBITOR -> METABOLIC ENZYME
none
Mediator Substance Details
none
Created by admin on Wed Aug 04 21:57:56 EDT 2021 , Edited by admin on Wed Aug 04 21:57:56 EDT 2021
SUBSTRATE -> METABOLIC ENZYME
none
Mediator Substance Details
none
Created by admin on Wed Aug 04 21:58:00 EDT 2021 , Edited by admin on Wed Aug 04 21:58:00 EDT 2021
SUBSTRATE -> METABOLIC ENZYME
none
Mediator Substance Details
none
Created by admin on Wed Aug 04 21:57:57 EDT 2021 , Edited by admin on Wed Aug 04 21:57:57 EDT 2021
SUBSTRATE -> METABOLIC ENZYME
none
Mediator Substance Details
none
Created by admin on Wed Aug 04 21:57:59 EDT 2021 , Edited by admin on Wed Aug 04 21:57:59 EDT 2021
INDUCER -> METABOLIC ENZYME
none
Mediator Substance Details
none
Created by admin on Wed Aug 04 21:58:00 EDT 2021 , Edited by admin on Wed Aug 04 21:58:00 EDT 2021
SUBSTRATE -> METABOLIC ENZYME
none
Mediator Substance Details
none
Created by admin on Wed Aug 04 21:57:57 EDT 2021 , Edited by admin on Wed Aug 04 21:57:57 EDT 2021
INHIBITOR -> METABOLIC ENZYME
Mediator Substance Details
none
WEAK
IC50
Created by admin on Wed Aug 04 21:58:05 EDT 2021 , Edited by admin on Wed Aug 04 21:58:05 EDT 2021
SUBSTRATE -> METABOLIC ENZYME
none
Mediator Substance Details
none
Created by admin on Wed Aug 04 21:58:01 EDT 2021 , Edited by admin on Wed Aug 04 21:58:01 EDT 2021
INHIBITOR -> METABOLIC ENZYME
Mediator Substance Details
none
POTENT
Created by admin on Wed Aug 04 21:57:52 EDT 2021 , Edited by admin on Wed Aug 04 21:57:52 EDT 2021
Structural Modifications
Modification Type Location Site Location Type Residue Modified Extent Modification Name Modification ID Access
Heme binding [1_435] CYS HEME-CYSTEINE (OXIDIZED) G0HAF1JK3T
Name Property Type Amount Referenced Substance Defining Parameters Access References
MOL_WEIGHT:NUMBER(CALCULATED) CHEMICAL
0
Molecular Formula CHEMICAL
0
Created Wed Aug 04 21:57:22 EDT 2021
Created By admin
Last Edited Wed Aug 04 21:57:22 EDT 2021
Last Edited By admin
Index Source Text / Citation Source Type Tags Date Accessed File Access
1 http://www.accessdata.fda.gov/drugsatfda_docs/label/2016/208246s000lbl.pdf DRUG PRODUCT LABEL NOMEN
2 The Role of Human Hepatic Cytochrome P450 Isozymes in the Metabolism of Racemic 3,4-Methylenedioxyethylamphetamine and Its Single Enantiomers Markus R. Meyer, Frank T. Peters and Hans H. Maurer Drug Metabolism and Disposition June 2009, 37 (6) 1152-1156; DOI: https://doi.org/10.1124/dmd.108.026203 JA PUBLIC_DOMAIN_RELEASE
3 https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/205858lbl.pdf FDA APPROVED DRUG LABEL PUBLIC_DOMAIN_RELEASE
4 fda_srs SRS NOMEN PUBLIC_DOMAIN_RELEASE AUTO_SELECTED
5 Nucleic Acids Research, 2010, Vol. 38, Database issue D237–D243 doi:10.1093/nar/gkp970 JA
6 https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/213756s000lbl.pdf FDA APPROVED DRUG LABEL PUBLIC_DOMAIN_RELEASE
7 Liu, Jinzhong, et al. "Inhibition of Cytochrome P450 Enzymes by the E-and Z-Isomers of Norendoxifen." Drug Metabolism and Disposition 41.9 (2013): 1715-1720. JA PUBLIC_DOMAIN_RELEASE
8 Patilea-Vrana, Gabriela I., Olena Anoshchenko, and Jashvant D. Unadkat. "Hepatic Enzymes Relevant to the Disposition of (?)-? 9-Tetrahydrocannabinol (THC) and Its Psychoactive Metabolite, 11-OH-THC." Drug Metabolism and Disposition 47.3 (2019): 249-256. JA PUBLIC_DOMAIN_RELEASE
9 https://www.accessdata.fda.gov/drugsatfda_docs/nda/2013/205123Orig1s000ClinPharmR.pdf NDA PUBLIC REVIEW PUBLIC_DOMAIN_RELEASE
10 http://www.aafp.org/afp/2007/0801/p391.html JOURNAL ARTICLE NOMEN
11 Kumar, Gondi N., et al. "Identification of cytochromes P450 involved in the human liver microsomal metabolism of the thromboxane A2 inhibitor seratrodast (ABT-001)." Drug metabolism and disposition 25.1 (1997): 110-115. JA PUBLIC_DOMAIN_RELEASE
12 PEDIATRIC DRUGS AUGUST 2003, VOLUME 5, ISSUE 8, PP 557?572 JOURNAL ARTICLE NOMEN
13 Wienkers, Larry C., and Michael A. Wynalda. "Multiple cytochrome P450 enzymes responsible for the oxidative metabolism of the substituted (S)-3-phenylpiperidine,(S, S)-3-[3-(methylsulfonyl) phenyl]-1-propylpiperidine hydrochloride, in human liver microsomes." Drug metabolism and disposition 30.12 (2002): 1372-1377. JA PUBLIC_DOMAIN_RELEASE
14 https://www.accessdata.fda.gov/drugsatfda_docs/label/2003/021602lbl.pdf NDA PUBLIC REVIEW PUBLIC_DOMAIN_RELEASE
15 Foxenberg, Robert J., et al. "Human hepatic cytochrome p450-specific metabolism of parathion and chlorpyrifos." Drug metabolism and disposition 35.2 (2007): 189-193. JA PUBLIC_DOMAIN_RELEASE
16 https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/213176s000lbl.pdf FDA APPROVED DRUG LABEL PUBLIC_DOMAIN_RELEASE
17 Generated from relationship on:'TOFACITINIB' SYSTEM
18 Dunkoksung, Wilasinee, et al. "Rhinacanthin-C Mediated Herb-Drug Interactions with Drug Transporters and Phase I Drug-Metabolizing Enzymes." Drug Metabolism and Disposition 47.10 (2019): 1040-1049. JA PUBLIC_DOMAIN_RELEASE
19 https://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/210923Orig1s000MultidisciplineR.pdf NDA PUBLIC REVIEW PUBLIC_DOMAIN_RELEASE
20 https://www.accessdata.fda.gov/drugsatfda_docs/nda/2013/203505Orig1s000ClinPharmR.pdf NDA PUBLIC REVIEW PUBLIC_DOMAIN_RELEASE
21 Yanni, Souzan B., et al. "In vitro hepatic metabolism explains higher clearance of voriconazole in children versus adults: role of CYP2C19 and flavin-containing monooxygenase 3." Drug Metabolism and Disposition 38.1 (2010): 25-31. JA PUBLIC_DOMAIN_RELEASE
22 Kazmi, Faraz, et al. "A long-standing mystery solved: the formation of 3-hydroxydesloratadine is catalyzed by CYP2C8 but prior glucuronidation of desloratadine by UDP-glucuronosyltransferase 2B10 is an obligatory requirement." Drug Metabolism and Disposition 43.4 (2015): 523-533. JA PUBLIC_DOMAIN_RELEASE
23 https://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/210496Orig1s000MultidisciplineR.pdf NDA PUBLIC REVIEW PUBLIC_DOMAIN_RELEASE
24 http://srsid.fda.gov:9618/ePS/SubstanceRelationship.do?substanceMode=select&FROM=SUBSTANCESEARCH&RELATEDSUBSTANCE_ID=120897&RELATEDBDNUM=0790954AA FDA APPROVED DRUG LABEL NOMEN
25 Xu, Lin, et al. "In vitro metabolism of BIIB021, an inhibitor of heat shock protein 90, in liver microsomes and hepatocytes of rats, dogs, and humans and recombinant human cytochrome P450 isoforms." Drug Metabolism and Disposition 40.4 (2012): 680-693. JA PUBLIC_DOMAIN_RELEASE
26 Peters, Frank T., et al. "Identification of Cytochrome P450 Enzymes Involved in the Metabolism of the New Designer Drug 4?-Methyl-?-pyrrolidinobutyrophenone." Drug metabolism and disposition 36.1 (2008): 163-168. JA PUBLIC_DOMAIN_RELEASE
27 https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/205353s000lbl.pdf FDA APPROVED DRUG LABEL PUBLIC_DOMAIN_RELEASE
28 https://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/212839Orig1s000ClinPharmR.pdf NDA PUBLIC REVIEW PUBLIC_DOMAIN_RELEASE
29 Wu, Jianmei, et al. "In vitro metabolism and drug-drug interaction potential of UTL-5g, a novel chemo-and radioprotective agent." Drug Metabolism and Disposition 42.12 (2014): 2058-2067. JA PUBLIC_DOMAIN_RELEASE
30 https://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/201699Orig1s000ClinPharmR.pdf NDA PUBLIC REVIEW PUBLIC_DOMAIN_RELEASE
31 https://www.accessdata.fda.gov/drugsatfda_docs/label/2004/21518lbl.pdf NDA PUBLIC REVIEW PUBLIC_DOMAIN_RELEASE
32 Wu, Jianmei, et al. "In vitro metabolism and drug-drug interaction potential of UTL-5g, a novel chemo-and radioprotective agent." Drug Metabolism and Disposition 42.12 (2014): 2058-2067. JA PUBLIC_DOMAIN_RELEASE
33 https://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/022399Orig1s000ClinPharmR.pdf NDA PUBLIC REVIEW PUBLIC_DOMAIN_RELEASE
34 STN STN (SCIFINDER)
35 Usmani, Khawja A., et al. "In vitro human metabolism and interactions of repellent N, N-diethyl-m-toluamide." Drug metabolism and disposition 30.3 (2002): 289-294. JA PUBLIC_DOMAIN_RELEASE
36 dump-public-2021-07-22_UPDATED.gsrs BATCH_IMPORT Wed Aug 04 21:56:50 EDT 2021
37 https://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/022522Orig1s000ClinPharmR.pdf NDA PUBLIC REVIEW PUBLIC_DOMAIN_RELEASE
38 https://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/208711Orig1s000MultidisciplineR.pdf NDA PUBLIC REVIEW PUBLIC_DOMAIN_RELEASE
39 https://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/212801Orig1s000ClinPharmR.pdf NDA PUBLIC REVIEW PUBLIC_DOMAIN_RELEASE
40 https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/040745Orig1s003lbl.pdf FDA APPROVED DRUG LABEL PUBLIC_DOMAIN_RELEASE
41 UNIPROT SRS NOMEN
42 Foxenberg, Robert J., et al. "Human hepatic cytochrome p450-specific metabolism of parathion and chlorpyrifos." Drug metabolism and disposition 35.2 (2007): 189-193. JA PUBLIC_DOMAIN_RELEASE
43 https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/205353s000lbl.pdf FDA APPROVED DRUG LABEL PUBLIC_DOMAIN_RELEASE
44 FDA_SRS SRS NOMEN
45 Gorman, Gregory S., et al. "In vitro metabolic characterization, phenotyping, and kinetic studies of 9cUAB30, a retinoid X receptor-specific retinoid." Drug metabolism and disposition 35.7 (2007): 1157-1164. JA PUBLIC_DOMAIN_RELEASE
46 Uchiyama, Minoru, et al. "In vitro metabolism of rivoglitazone, a novel peroxisome proliferator-activated receptor ? agonist, in rat, monkey, and human liver microsomes and freshly isolated hepatocytes." Drug metabolism and disposition 39.7 (2011): 1311-1319. JA PUBLIC_DOMAIN_RELEASE
47 https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/020705s018lbl.pdf FDA APPROVED DRUG LABEL PUBLIC_DOMAIN_RELEASE
48 ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, NOV. 2003, P. 3464?3469 JOURNAL ARTICLE NOMEN
49 https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/203415Orig1s000ClinPharmR.pdf NDA PUBLIC REVIEW PUBLIC_DOMAIN_RELEASE
50 https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210910s000lbl.pdf NDA PUBLIC REVIEW PUBLIC_DOMAIN_RELEASE
51 https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/213969s000lbl.pdf FDA APPROVED DRUG LABEL PUBLIC_DOMAIN_RELEASE
52 SRS CODE IMPORT SRS NOMEN Fri Apr 28 15:02:50 EDT 2017
53 Jensen, Klaus Gjervig, and Lars Dalgaard. "In vitro metabolism of the M1-muscarinic agonist 5-(2-ethyl-2H-tetrazol-5-yl)-1-methyl-1, 2, 3, 6-tetrahydropyridine by human hepatic cytochromes P-450 determined at pH 7.4 and 8.5." Drug metabolism and disposition 27.1 (1999): 125-132. JA PUBLIC_DOMAIN_RELEASE
54 Guo, Jian, et al. "In vitro metabolism of isoliquiritigenin by human liver microsomes." Drug metabolism and disposition 36.2 (2008): 461-468. JA PUBLIC_DOMAIN_RELEASE
55 Talakad, Jyothi C., et al. "Comparison of in vitro metabolism of ticlopidine by human cytochrome P450 2B6 and rabbit cytochrome P450 2B4." Drug metabolism and disposition 39.3 (2011): 539-550. JA PUBLIC_DOMAIN_RELEASE
56 DRUG METABOLISM HANDBOOK, ED. A.F. NASSER, 2009, PG:371 BOOK NOMEN
57 Fujita, Ken-ichi, et al. "N-Isopropyl-p-iodoamphetamine hydrochloride is predominantly metabolized by CYP2C19." Drug metabolism and disposition 40.5 (2012): 843-846. JA PUBLIC_DOMAIN_RELEASE
58 https://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/209229Orig1s000MultidisciplineR.pdf NDA PUBLIC REVIEW PUBLIC_DOMAIN_RELEASE
59 Volotinen, Marjo, et al. "Timolol metabolism in human liver microsomes is mediated principally by CYP2D6." Drug metabolism and disposition 35.7 (2007): 1135-1141. JA PUBLIC_DOMAIN_RELEASE
60 Generated from relationship on:'ATOMOXETINE' SYSTEM
61 https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/205858lbl.pdf FDA APPROVED DRUG LABEL PUBLIC_DOMAIN_RELEASE
62 R Meyer, Markus, and Hans H Maurer. "Metabolism of designer drugs of abuse: an updated review." Current drug metabolism 11.5 (2010): 468-482. JA PUBLIC_DOMAIN_RELEASE
63 https://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/210868Orig1s000MultidisciplineR.pdf NDA PUBLIC REVIEW PUBLIC_DOMAIN_RELEASE
64 Kassahun, Kelem, et al. "Role of human liver cytochrome P4503A in the metabolism of etoricoxib, a novel cyclooxygenase-2 selective inhibitor." Drug metabolism and disposition 29.6 (2001): 813-820. JA PUBLIC_DOMAIN_RELEASE
65 Daher, Wassim, et al. "In vitro metabolism of ferroquine (SSR97193) in animal and human hepatic models and antimalarial activity of major metabolites on Plasmodium falciparum." Drug metabolism and disposition 34.4 (2006): 667-682. JA PUBLIC_DOMAIN_RELEASE
66 https://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/210450Orig1s000MultiD.pdf NDA PUBLIC REVIEW PUBLIC_DOMAIN_RELEASE
67 https://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/022567Orig1s000SumR.pdf NDA PUBLIC REVIEW PUBLIC_DOMAIN_RELEASE
68 Akutsu, Tomoko, et al. "Identification of human cytochrome p450 isozymes involved in diphenhydramine N-demethylation." Drug metabolism and disposition 35.1 (2007): 72-78. JA PUBLIC_DOMAIN_RELEASE
69 https://www.accessdata.fda.gov/drugsatfda_docs/label/2001/21341lbl.pdf NDA PUBLIC REVIEW PUBLIC_DOMAIN_RELEASE
70 The Role of Human Hepatic Cytochrome P450 Isozymes in the Metabolism of Racemic 3,4-Methylenedioxyethylamphetamine and Its Single Enantiomers Markus R. Meyer, Frank T. Peters and Hans H. Maurer Drug Metabolism and Disposition June 2009, 37 (6) 1152-1156; DOI: https://doi.org/10.1124/dmd.108.026203 JA PUBLIC_DOMAIN_RELEASE
71 https://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/208711Orig1s000MultidisciplineR.pdf NDA PUBLIC REVIEW PUBLIC_DOMAIN_RELEASE
72 https://www.accessdata.fda.gov/drugsatfda_docs/nda/2014/205677Orig1s000ClinPharmR.pdf NDA PUBLIC REVIEW PUBLIC_DOMAIN_RELEASE
73 https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/210730s000lbl.pdf FDA APPROVED DRUG LABEL PUBLIC_DOMAIN_RELEASE
74 Pharmacokinetics and Disposition of Momelotinib Revealed a Disproportionate Human Metabolite—Resolution for Clinical Development Jim Zheng, Yan Xin, Jingyu Zhang, Raju Subramanian, Bernard P. Murray, J. Andrew Whitney, Matthew R. Warr, John Ling, Lisa Moorehead, Ellen Kwan, Jeffrey Hemenway, Bill J. Smith and Jeffrey A. Silverman Drug Metabolism and Disposition March 2018, 46 (3) 237-247; DOI: https://doi.org/10.1124/dmd.117.078899 JA PUBLIC_DOMAIN_RELEASE
75 Subrahmanyam, Vangala, et al. "Identification of cytochrome P-450 isoforms responsible for cis-tramadol metabolism in human liver microsomes." Drug Metabolism and Disposition 29.8 (2001): 1146-1155. JA PUBLIC_DOMAIN_RELEASE
76 https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/203858Orig1s000ClinpharmR.pdf NDA PUBLIC REVIEW PUBLIC_DOMAIN_RELEASE
77 Sridar, Chitra, Cesar Kenaan, and Paul F. Hollenberg. "Inhibition of bupropion metabolism by selegiline: mechanism-based inactivation of human CYP2B6 and characterization of glutathione and peptide adducts." Drug Metabolism and Disposition 40.12 (2012): 2256-2266. JA PUBLIC_DOMAIN_RELEASE
78 http://www.aafp.org/afp/2007/0801/p391.html#afp20070801p391-t1 JOURNAL ARTICLE NOMEN
79 R Meyer, Markus, and Hans H Maurer. "Metabolism of designer drugs of abuse: an updated review." Current drug metabolism 11.5 (2010): 468-482. JA PUBLIC_DOMAIN_RELEASE
80 https://www.accessdata.fda.gov/drugsatfda_docs/nda/2013/205123Orig1s000ClinPharmR.pdf NDA PUBLIC REVIEW PUBLIC_DOMAIN_RELEASE
81 https://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/212028Orig1s000MultidisciplineR.pdf NDA PUBLIC REVIEW PUBLIC_DOMAIN_RELEASE
82 https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/022529Orig1s000ClinPharmR.pdf NDA PUBLIC REVIEW PUBLIC_DOMAIN_RELEASE
83 Generated from relationship on:'BRIVARACETAM' SYSTEM
84 Obach, R. Scott, and Tim F. Ryder. "Metabolism of ramelteon in human liver microsomes and correlation with the effect of fluvoxamine on ramelteon pharmacokinetics." Drug metabolism and disposition 38.8 (2010): 1381-1391. JA PUBLIC_DOMAIN_RELEASE
85 LAURENCE S. KAMINSKY; HUMAN P450 METABOLISM OF WARFARIN; PHARMACOLOGY & THERAPEUTICS;\\nVOLUME 73, ISSUE 1, 1997, PAGES 67?74 JOURNAL ARTICLE NOMEN
86 Kilicarslan, Tansel, et al. "Flunitrazepam metabolism by cytochrome P450s 2C19 and 3A4." Drug metabolism and disposition 29.4 (2001): 460-465. JA PUBLIC_DOMAIN_RELEASE
87 https://www.accessdata.fda.gov/drugsatfda_docs/nda/2010/200603Orig1s000ClinPharmR.pdf NDA PUBLIC REVIEW PUBLIC_DOMAIN_RELEASE
88 https://www.accessdata.fda.gov/drugsatfda_docs/label/2003/021503lbl.pdf FDA APPROVED DRUG LABEL PUBLIC_DOMAIN_RELEASE
89 Dulac, Martin, et al. "Metabolism of anethole dithiolethione by rat and human liver microsomes: formation of various products deriving from its O-demethylation and S-oxidation. Involvement of cytochromes P450 and flavin monooxygenases in these pathways." Drug Metabolism and Disposition 46.10 (2018): 1390-1395. JA PUBLIC_DOMAIN_RELEASE
90 Ramírez, Jacqueline, et al. "CYP2B6, CYP3A4, and CYP2C19 are responsible for the in vitro N-demethylation of meperidine in human liver microsomes." Drug metabolism and disposition 32.9 (2004): 930-936. JA PUBLIC_DOMAIN_RELEASE
91 https://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/210450Orig1s000MultiD.pdf NDA PUBLIC REVIEW PUBLIC_DOMAIN_RELEASE
92 STN STN (SCIFINDER)
93 https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/208462lbl.pdf NDA PUBLIC REVIEW PUBLIC_DOMAIN_RELEASE
94 https://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/022567Orig1s000SumR.pdf NDA PUBLIC REVIEW PUBLIC_DOMAIN_RELEASE
95 Generated from relationship on:'TOPIRAMATE' SYSTEM
96 Metabolism and Disposition of Cabozantinib in Healthy Male Volunteers and Pharmacologic Characterization of Its Major Metabolites Steven Lacy, Bih Hsu, Dale Miles, Dana Aftab, Ronghua Wang and Linh Nguyen Drug Metabolism and Disposition August 2015, 43 (8) 1190-1207; DOI: https://doi.org/10.1124/dmd.115.063610 JA PUBLIC_DOMAIN_RELEASE
97 https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/204569s000lbledt.pdf NDA PUBLIC REVIEW PUBLIC_DOMAIN_RELEASE
98 https://www.accessdata.fda.gov/drugsatfda_docs/nda/2009/022268s000_ClinPharmR.pdf NDA PUBLIC REVIEW PUBLIC_DOMAIN_RELEASE
99 https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/202992Orig1s000ClinpharmR.pdf NDA PUBLIC REVIEW PUBLIC_DOMAIN_RELEASE
100 Liu, Jinzhong, et al. "Inhibition of Cytochrome P450 Enzymes by the E-and Z-Isomers of Norendoxifen." Drug Metabolism and Disposition 41.9 (2013): 1715-1720. JA PUBLIC_DOMAIN_RELEASE
101 http://www.uniprot.org/uniprot/P33261 SRS NOMEN
102 Zhang, Wenjiang, et al. "Metabolism of 18-methoxycoronaridine, an ibogaine analog, to 18-hydroxycoronaridine by genetically variable CYP2C19." Drug metabolism and disposition 30.6 (2002): 663-669. JA PUBLIC_DOMAIN_RELEASE
103 https://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/208627Orig1s000SumR.pdf NDA PUBLIC REVIEW PUBLIC_DOMAIN_RELEASE
104 https://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/202022Orig1s000ClinPharmR.pdf NDA PUBLIC REVIEW PUBLIC_DOMAIN_RELEASE
105 Ellison, Corie A., et al. "Human hepatic cytochrome P450-specific metabolism of the organophosphorus pesticides methyl parathion and diazinon." Drug Metabolism and Disposition 40.1 (2012): 1-5. JA PUBLIC_DOMAIN_RELEASE
106 https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/204410s000lbl.pdf NDA PUBLIC REVIEW PUBLIC_DOMAIN_RELEASE
107 R Meyer, Markus, and Hans H Maurer. "Metabolism of designer drugs of abuse: an updated review." Current drug metabolism 11.5 (2010): 468-482. JA PUBLIC_DOMAIN_RELEASE
108 https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/208711s000lbl.pdf NDA PUBLIC REVIEW PUBLIC_DOMAIN_RELEASE
109 SRS import [081I12ZA58] SRS NOMEN Fri Apr 28 15:02:50 EDT 2017
110 https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/213969s000lbl.pdf FDA APPROVED DRUG LABEL PUBLIC_DOMAIN_RELEASE
111 https://www.accessdata.fda.gov/drugsatfda_docs/nda/2007/022081s000_ClinPharmR_P1.pdf NDA PUBLIC REVIEW PUBLIC_DOMAIN_RELEASE
112 https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=7e467c02-49a0-4b62-b537-430fdfa4f10e DAILYMED
113 Generated from relationship on:'TOFACITINIB' SYSTEM
114 R Meyer, Markus, and Hans H Maurer. "Metabolism of designer drugs of abuse: an updated review." Current drug metabolism 11.5 (2010): 468-482. JA PUBLIC_DOMAIN_RELEASE
115 https://www.accessdata.fda.gov/drugsatfda_docs/nda/2016/209115Orig1s000MultiDisciplineR.pdf NDA PUBLIC REVIEW PUBLIC_DOMAIN_RELEASE
116 Gong, Jiachang, Lars Hansen, and Lisa Iacono. "Clinical Pharmacokinetics and the Impact of Genetic Polymorphism on a CYP2C19 Substrate, BMS-823778, in Healthy Subjects." Drug Metabolism and Disposition 46.3 (2018): 316-325. JA PUBLIC_DOMAIN_RELEASE
117 https://www.accessdata.fda.gov/drugsatfda_docs/label/2008/022023lbl.pdf NDA PUBLIC REVIEW PUBLIC_DOMAIN_RELEASE
118 https://www.accessdata.fda.gov/drugsatfda_docs/label/2002/21266lbl.pdf FDA APPROVED DRUG LABEL PUBLIC_DOMAIN_RELEASE
119 https://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/212327Orig1s000MultidisciplineR.pdf NDA PUBLIC REVIEW PUBLIC_DOMAIN_RELEASE
120 https://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/213217Orig1s000MultidisciplineR.pdf NDA PUBLIC REVIEW PUBLIC_DOMAIN_RELEASE
121 von Moltke, Lisa L., et al. "Escitalopram (S-citalopram) and its metabolites in vitro: cytochromes mediating biotransformation, inhibitory effects, and comparison to R-citalopram." Drug Metabolism and Disposition 29.8 (2001): 1102-1109. JA PUBLIC_DOMAIN_RELEASE
122 Metabolism and Disposition of Cabozantinib in Healthy Male Volunteers and Pharmacologic Characterization of Its Major Metabolites Steven Lacy, Bih Hsu, Dale Miles, Dana Aftab, Ronghua Wang and Linh Nguyen Drug Metabolism and Disposition August 2015, 43 (8) 1190-1207; DOI: https://doi.org/10.1124/dmd.115.063610 JA PUBLIC_DOMAIN_RELEASE
123 https://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/212862Orig1s000MultidisciplineR.pdf NDA PUBLIC REVIEW PUBLIC_DOMAIN_RELEASE
124 https://www.accessdata.fda.gov/drugsatfda_docs/nda/2008/022253s000_022254s000_ClinPharmR_P1.pdf NDA PUBLIC REVIEW PUBLIC_DOMAIN_RELEASE
125 https://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/212839Orig1s000ClinPharmR.pdf NDA PUBLIC REVIEW PUBLIC_DOMAIN_RELEASE
126 https://www.accessdata.fda.gov/drugsatfda_docs/nda/2001/20831_Foradil_prntlbl.pdf NDA PUBLIC REVIEW PUBLIC_DOMAIN_RELEASE
127 Yu, Bang-Ning, et al. "Pharmacokinetics of citalopram in relation to genetic polymorphism of CYP2C19." Drug metabolism and disposition 31.10 (2003): 1255-1259. JA PUBLIC_DOMAIN_RELEASE
128 R Meyer, Markus, and Hans H Maurer. "Metabolism of designer drugs of abuse: an updated review." Current drug metabolism 11.5 (2010): 468-482. JA PUBLIC_DOMAIN_RELEASE
129 Franklin, Michael R., and Laura B. Hathaway. "2-Diethylaminoethyl-2, 2-diphenylvalerate-HCl (SKF525A) revisited: comparative cytochrome P450 inhibition in human liver microsomes by SKF525A, its metabolites, and SKF-acid and SKF-alcohol." Drug metabolism and disposition 36.12 (2008): 2539-2546. JA PUBLIC_DOMAIN_RELEASE
130 Further Characterization of the Metabolism of Desloratadine and Its Cytochrome P450 and UDP-glucuronosyltransferase Inhibition Potential: Identification of Desloratadine as a Relatively Selective UGT2B10 Inhibitor Faraz Kazmi, Phyllis Yerino, Joanna E. Barbara and Andrew Parkinson Drug Metabolism and Disposition September 2015, 43 (9) 1294-1302; DOI: https://doi.org/10.1124/dmd.115.065011 JA PUBLIC_DOMAIN_RELEASE
131 Walles, Markus, et al. "Metabolism and disposition of the metabotropic glutamate receptor 5 antagonist (mGluR5) mavoglurant (AFQ056) in healthy subjects." Drug Metabolism and Disposition 41.9 (2013): 1626-1641. JA PUBLIC_DOMAIN_RELEASE
132 STN SRS NOMEN
133 McClue, Steven J., and Iain Stuart. "Metabolism of the trisubstituted purine cyclin-dependent kinase inhibitor seliciclib (R-roscovitine) in vitro and in vivo." Drug metabolism and disposition 36.3 (2008): 561-570. JA PUBLIC_DOMAIN_RELEASE
134 https://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/202067Orig1s000ClinPharmR.pdf NDA PUBLIC REVIEW
135 Metabolism of a 5HT6 Antagonist, 2-Methyl-1-(Phenylsulfonyl)-4-(Piperazin-1-yl)-1H-Benzo[d]imidazole (SAM-760): Impact of Sulfonamide Metabolism on Diminution of a Ketoconazole-Mediated Clinical Drug-Drug Interaction Aarti Sawant-Basak, R. Scott Obach, Angela Doran, Peter Lockwood, Klaas Schildknegt, Hongying Gao, Jessica Mancuso, Susanna Tse and Thomas A. Comery Drug Metabolism and Disposition July 2018, 46 (7) 934-942; DOI: https://doi.org/10.1124/dmd.118.080457 JA PUBLIC_DOMAIN_RELEASE
136 http://www.accessdata.fda.gov/drugsatfda_docs/label/2016/208246s000lbl.pdf DRUG PRODUCT LABEL NOMEN
137 The Role of Human Hepatic Cytochrome P450 Isozymes in the Metabolism of Racemic 3,4-Methylenedioxy-Methamphetamine and Its Enantiomers Markus R. Meyer, Frank T. Peters and Hans H. Maurer Drug Metabolism and Disposition November 2008, 36 (11) 2345-2354; DOI: https://doi.org/10.1124/dmd.108.021543 JA PUBLIC_DOMAIN_RELEASE
138 Talakad, Jyothi C., et al. "Comparison of in vitro metabolism of ticlopidine by human cytochrome P450 2B6 and rabbit cytochrome P450 2B4." Drug metabolism and disposition 39.3 (2011): 539-550. JA PUBLIC_DOMAIN_RELEASE
139 http://dmd.aspetjournals.org/content/39/4/693 WEBSITE NOMEN
140 https://www.accessdata.fda.gov/drugsatfda_docs/nda/2015/207500Orig1207501Orig1s000ClinPharmR.pdf NDA PUBLIC REVIEW
141 In Vitro Metabolism of 2-[6-(4-Chlorophenyl)-2,2-dimethyl-7-phenyl-2,3-dihydro-1H-pyrrolizin-5-yl] Acetic Acid (Licofelone, ML3000), an Inhibitor of Cyclooxygenase-1 and -2 and 5-Lipoxygenase Wolfgang Albrecht, Anke Unger, Andreas K. Nussler and Stefan Laufer Drug Metabolism and Disposition May 2008, 36 (5) 894-903; DOI: https://doi.org/10.1124/dmd.108.020347 JA PUBLIC_DOMAIN_RELEASE
142 Kochansky, Christopher J., et al. "Absorption, metabolism, and excretion of [14C] MK-0767 (2-methoxy-5-(2, 4-dioxo-5-thiazolidinyl)-N-[[4-(trifluoromethyl) phenyl] methyl] benzamide) in humans." Drug metabolism and disposition 34.9 (2006): 1457-1461. JA PUBLIC_DOMAIN_RELEASE
143 https://www.accessdata.fda.gov/drugsatfda_docs/nda/2017/209606Orig1s000MultidisciplineR.pdf NDA PUBLIC REVIEW PUBLIC_DOMAIN_RELEASE
144 Gantenbein, Manon, et al. "Oxidative metabolism of bupivacaine into pipecolylxylidine in humans is mainly catalyzed by CYP3A." Drug metabolism and disposition 28.4 (2000): 383-385. JA PUBLIC_DOMAIN_RELEASE
145 https://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/211810Orig1s000MultidisciplineR.pdf NDA PUBLIC REVIEW PUBLIC_DOMAIN_RELEASE
146 https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/214094s000lbl.pdf FDA APPROVED DRUG LABEL PUBLIC_DOMAIN_RELEASE
147 Kochansky, Christopher J., et al. "Absorption, metabolism, and excretion of [14C] MK-0767 (2-methoxy-5-(2, 4-dioxo-5-thiazolidinyl)-N-[[4-(trifluoromethyl) phenyl] methyl] benzamide) in humans." Drug metabolism and disposition 34.9 (2006): 1457-1461. JA PUBLIC_DOMAIN_RELEASE
148 Wang, Bonnie, et al. "The involvement of CYP3A4 and CYP2C9 in the metabolism of 17?-ethinylestradiol." Drug metabolism and disposition 32.11 (2004): 1209-1212. JA PUBLIC_DOMAIN_RELEASE
149 Ellison, Corie A., et al. "Human hepatic cytochrome P450-specific metabolism of the organophosphorus pesticides methyl parathion and diazinon." Drug Metabolism and Disposition 40.1 (2012): 1-5. JA PUBLIC_DOMAIN_RELEASE
150 http://www.health.harvard.edu/diseases-and-conditions/proton-pump-inhibitors WEBSITE NOMEN
151 Generated from relationship on:'WARFARIN, (R)-' SYSTEM
152 Li, Xiaofeng, et al. "Disposition and drug-drug interaction potential of veliparib (ABT-888), a novel and potent inhibitor of poly (ADP-ribose) polymerase." Drug metabolism and disposition 39.7 (2011): 1161-1169. JA PUBLIC_DOMAIN_RELEASE
153 https://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/213137Orig1s000Multidiscipline.pdf NDA PUBLIC REVIEW PUBLIC_DOMAIN_RELEASE
154 https://www.accessdata.fda.gov/drugsatfda_docs/nda/99/21-014_TRILEPTAL_biopharmr_P1.pdf NDA PUBLIC REVIEW PUBLIC_DOMAIN_RELEASE
155 Generated from relationship on:'OXYMETAZOLINE' SYSTEM
156 Zheng, Nan, et al. "In vitro metabolism of 17-(dimethylaminoethylamino)-17-demethoxygeldanamycin in human liver microsomes." Drug metabolism and disposition 39.4 (2011): 627-635. JA PUBLIC_DOMAIN_RELEASE
157 Obach, R. Scott, and Tim F. Ryder. "Metabolism of ramelteon in human liver microsomes and correlation with the effect of fluvoxamine on ramelteon pharmacokinetics." Drug metabolism and disposition 38.8 (2010): 1381-1391. JA PUBLIC_DOMAIN_RELEASE
158 https://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/211349Orig1s000MultidisciplineR.pdf NDA PUBLIC REVIEW PUBLIC_DOMAIN_RELEASE
159 https://www.accessdata.fda.gov/drugsatfda_docs/nda/2009/022395s000ClinPharmr.pdf NDA PUBLIC REVIEW PUBLIC_DOMAIN_RELEASE
160 Yu, Jian, Dean G. Brown, and Doug Burdette. "In vitro metabolism studies of nomifensine monooxygenation pathways: metabolite identification, reaction phenotyping, and bioactivation mechanism." Drug metabolism and disposition 38.10 (2010): 1767-1778. JA PUBLIC_DOMAIN_RELEASE
161 Franklin, Michael R., and Laura B. Hathaway. "2-Diethylaminoethyl-2, 2-diphenylvalerate-HCl (SKF525A) revisited: comparative cytochrome P450 inhibition in human liver microsomes by SKF525A, its metabolites, and SKF-acid and SKF-alcohol." Drug metabolism and disposition 36.12 (2008): 2539-2546. JA PUBLIC_DOMAIN_RELEASE
162 Pedersen, Anders Just, Trine Hedebrink Petersen, and Kristian Linnet. "In vitro metabolism and pharmacokinetic studies on methylone." Drug Metabolism and Disposition 41.6 (2013): 1247-1255. JA PUBLIC_DOMAIN_RELEASE
163 https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/208711s000lbl.pdf NDA PUBLIC REVIEW PUBLIC_DOMAIN_RELEASE
164 EPILEPSIU, 41(SUPPL. I):S61-S65, 2000 JOURNAL ARTICLE NOMEN
165 Franklin, Michael R., and Laura B. Hathaway. "2-Diethylaminoethyl-2, 2-diphenylvalerate-HCl (SKF525A) revisited: comparative cytochrome P450 inhibition in human liver microsomes by SKF525A, its metabolites, and SKF-acid and SKF-alcohol." Drug metabolism and disposition 36.12 (2008): 2539-2546. JA PUBLIC_DOMAIN_RELEASE
166 Yamamoto, Takahito, et al. "Differences in Cytochrome P450 Forms Involved in the Metabolism ofN, N-Dipropyl-2-[4-methoxy-3-(2-phenylethoxy) phenyl] ethylamine monohydrochloride (NE-100), a Novel Sigma Ligand, in Human Liver and Intestine." Drug metabolism and disposition 31.1 (2003): 60-66. JA PUBLIC_DOMAIN_RELEASE
167 Hicks, J. Kevin, et al. "Clinical pharmacogenetics implementation consortium guideline (CPIC) for CYP2D6 and CYP2C19 genotypes and dosing of tricyclic antidepressants: 2016 update." Clinical Pharmacology & Therapeutics 102.1 (2017): 37-44. JA
168 Kochansky, Christopher J., et al. "Absorption, metabolism, and excretion of [14C] MK-0767 (2-methoxy-5-(2, 4-dioxo-5-thiazolidinyl)-N-[[4-(trifluoromethyl) phenyl] methyl] benzamide) in humans." Drug metabolism and disposition 34.9 (2006): 1457-1461. JA PUBLIC_DOMAIN_RELEASE
169 Hu, Yiding, and David Kupfer. "Metabolism of the endocrine disruptor pesticide-methoxychlor by human P450s: pathways involving a novel catechol metabolite." Drug metabolism and disposition 30.9 (2002): 1035-1042. JA PUBLIC_DOMAIN_RELEASE
170 Subrahmanyam, Vangala, et al. "Identification of cytochrome P-450 isoforms responsible for cis-tramadol metabolism in human liver microsomes." Drug Metabolism and Disposition 29.8 (2001): 1146-1155. JA PUBLIC_DOMAIN_RELEASE
171 https://www.accessdata.fda.gov/drugsatfda_docs/nda/2013/203505Orig1s000ClinPharmR.pdf NDA PUBLIC REVIEW PUBLIC_DOMAIN_RELEASE